Avalo Therapeutics Promotes Dr. Garry Neil to CEO & Chris Sullivan to CFO.

Published on : Published by : BioBuzz Media

On February 14, 2022 and effective immediately, the Company’s Board of Directors appointed Garry Neil, Chief Scientific Officer, as Chief Executive Officer and Chris Sullivan, Chief Accounting Officer, as Chief Financial Officer. The Company’s research and development group will continue to report to Dr. Neil. Mike Cola and Schond Greenway have stepped away from their prior roles as Chief Executive Officer and Chief Financial Officer, respectively, to pursue other interests.

Avalo Reports Positive Phase 1b Results for AVTX-002 in Moderate to Severe Crohn’s Disease Patients and Presents Additional Program Updates at 2022 Investor Event

Avalo Therapeutics logo
Published on : Published by : BioBuzz Media

Avalo Therapeutics, Inc. (Nasdaq: AVTX), a leading clinical-stage precision medicine company that discovers, develops, and commercializes targeted therapeutics for patients with significant unmet clinical need in immunology and rare genetic diseases, today provides a comprehensive update on the Company’s growth opportunities and mid-stage development portfolio.

Cerecor Rebrands to Avalo Therapeutics

Published on : Published by : Alex Keown

Cerecor Rebrands to Avalo Therapeutics. Eighteen months after completing its merger with Aevi Genomic Medicine, Cerecor is rebranding to Avalo Therapeutics. The rebranding to Avalo reflects the company’s aims to focus on three core indications, on immunology, immuno-oncology, and rare genetic diseases.